It focuses on commercializing technologies for life science research as well as bioprinting, and its products often combine capabilities in artificial intelligence, robotics, multiomics, and diagnostics.

[2] Bico Group (then Cellink) began by producing bio-inks and bioprinters for culturing different cell types to enable applications like patient-derived implants.

[4] They developed and sold the world's first universally compatible bio-ink to simplify bioprinting for academics and pharmaceutical companies who were, at that time, mixing their own biomaterial in-house.

[15] Bico Group transitioned to a bioconvergence company in 2020, expanding its focus from bioprinting to broader life sciences technology and industrial solutions.

[buzzword][2] The company develops and markets products that enable researchers to culture cells in 3D, perform high-throughput drug screening, and print human tissues and organs for use in medical, pharmaceutical and cosmetic applications.